1. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: 194-200.
2. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-86.
3. Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med 2015; 162: 335-44.
4. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-93.
5. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-22.
6. El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96.
7. Schillaci G, De Socio GV, Pucci G, et al. Aortic stiffness in untreated adult patients with human immunodeficiency virus infection. Hypertension 2008; 52: 308-13.
8. Baker JV, Duprez D, Rapkin J, et al. Untreated HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr 2009; 52: 25-31.
9. Sevastianova K, Sutinen J, Westerbacka J, Ristola M, Yki-Järvinen H. Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy. Antivir Ther (Lond) 2005; 10: 925-35.
10. Schillaci G, De Socio GV, Pirro M, et al. Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. Arterioscler Thromb Vasc Biol 2005; 25: 2381-5.
11. Lekakis J, Ikonomidis I, Palios J, et al. Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus. Am J Hypertens 2009; 22: 828-34.
12. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52: 569-76.
13. Finkelstein SM, Cohn JN. First- and third-order models for determining arterial compliance. J Hypertens 1992; 10: 11-4.
14. Duprez DA, Jacobs DR Jr, Lutsey PL, et al. Race/ethnic and sex differences in large and small artery elasticity–results of the multi-ethnic study of atherosclerosis (MESA). Ethn Dis 2009; 19: 243-50.
15. Valappil NI, Jacobs DR, Duprez DA, et al. Association between endothelial biomarkers and arterial elasticity in young adults – The CARDIA Study. J Am Soc Hypertens 2008; 2: 70-9.
16. Zimlichman R, Shargorodsky M, Boaz M, et al. Determination of arterial compliance using blood pressure waveform analysis with the CR-2000 system: Reliability, repeatability, and establishment of normal values for healthy European population–the seven European sites study (SESS). Am J Hypertens 2005; 18: 65-71.
17. Baker JV, Hullsiek KH, Engen NW, et al. Early antiretroviral therapy at high CD4 counts does not improve arterial elasticity: a substudy of the strategic timing of antiretroviral treatment (START) trial. Open Forum Infect Dis 2016; 3: ofw213.
18. van Vonderen MG, Hassink EA, van Agtmael MA, et al. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 2009; 199: 1186-94.
19. Ho JE, Deeks SG, Hecht FM, et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010; 24: 1897-905.
20. Maia-Leite LH, Catez E, Boyd A, et al. Aortic stiffness aging is influenced by past profound immunodeficiency in HIV-infected individuals: results from the EVAS-HIV (EValuation of Aortic Stiffness in HIV-infected individuals). J Hypertens 2016; 34: 1338-46.
21. Monteiro P, Miranda-Filho D, Bandeira F, et al. Is arterial stiffness in HIV-infected individuals associated with HIV-related factors? Braz J Med Biol Res 2012; 45: 818-26.
22. Echeverría P, Bonjoch A, Moltó J, et al. Pulse wave velocity as index of arterial stiffness in HIV-infected patients compared with a healthy population. J Acquir Immune Defic Syndr 2014; 65: 50-6.
23. Leite LHM, Cohen A, Boccara F. HIV infection and aortic stiffness. Arch Cardiovasc Dis 2017; 17: S1875-2136.
24. Gleason RL Jr, Caulk W, Seifu D, et al. Current efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia. PLoS One 2015, 10: e0117125.
25. Winer N, Sowers J and Weber M. Gender differences in vascular compliance in young, healthy subjects assessed by pulse contour analysis. J Clin Hypertens (Greenwich) 2001; 3: 145-52.
26. Guidelines on when to start ARV for HIV. World Health Organization. 2015. In: http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en; accessed July 2017.